facing_the_challenge_one_year_on

facing_the_challenge_one_year_on - FACING THE CHALLENGE ONE...

Info iconThis preview shows pages 1–4. Sign up to view the full content.

View Full Document Right Arrow Icon
FACING THE CHALLENGE ONE YEAR ON A progress report on our contribution to improving healthcare in the developing world
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
URUNDI CAMBODIA CAPE VERDE CENTRA C CHAD COMOROS DJIBOUTI ERITREA R T T U TU ISTAN URUND C ERITREA BISSAU KIRIBATI ANGOLA BANGLADESH FASO BURUNDI CAMBODIA CAPE VERDE REPUBLIC CHAD COMOROS DJIBOUTI DR L • C SEYCHELLES SEYCHEL FACING THE CHALLENGE ONE YEAR ON 02 IN ‘FACING THE CHALLENGE’ 1 WE PROMISED THAT WE WOULD SUPPLY OUR ANTIRETROVIRALS 2 AND ANTI-MALARIALS AT SUSTAINABLE PREFERENTIAL PRICES TO ELIGIBLE CUSTOMERS IN THE LEAST DEVELOPED COUNTRIES AND ALL SUB-SAHARAN AFRICAN COUNTRIES. THE 63 COUNTRIES IN WHICH THESE PRICES ARE AVAILABLE ARE: Eligible customers include the public sector, not-for-profit NGOs, aid agencies, UN agencies and international purchase funds such as the Global Fund to fight AIDS, TB and Malaria. Additionally, because of the gravity of the situation in sub-Saharan Africa, employers there who offer HIV/AIDS care and treatment directly to their staff through workplace clinics are also eligible. In addition, we will continue our existing commitment to the UN-led Accelerating Access Initiative (AAI). This involves antiretroviral medicines being available at discounted prices to participating countries. 1 http://corp.gsk.com/community/facing_the_challenge.pdf 2 GSK’s antiretrovirals are: Retrovir (AZT), Epivir , Combivir , Ziagen , Agenerase and Trizivir CONTENTS 4&5 Preferential Pricing Arrangements 6&7 Research and Development 8 Community Investment 9 A Global Partnership 10 Our Commitment 11 GlaxoSmithKline Principles
Background image of page 2
The problem, which is rooted in poverty, demands a significant mobilisation of resources, an unprecedented sense of urgency and a new spirit of partnership. At GlaxoSmithKline, we believe we have a vital contribution to make. In June 2001, GSK published ‘Facing the Challenge’, a document setting out our commitment and contribution to improving healthcare in the developing world. We outlined three key areas in which we would make an innovative, responsible and, above all, sustainable contribution: preferential pricing on our antiretrovirals (ARVs) and anti-malarials to a wide range of eligible customers in the Least Developed Countries and sub-Saharan Africa; investment in targets diseases that particularly affect the developing world; and community investment activities and partnerships that foster effective healthcare. In ‘Facing the Challenge’, we said that we would report on our activities. We are now honouring that commitment. We have seen significant progress which is highlighted on this page. Other stakeholders have also taken important steps in the last 12 months – the commitments made at the UN General Assembly Special Session on HIV/AIDS, the setting up of the Global Fund, and ARV treatment guidelines from the WHO are just some of the developments that have begun to remove the barriers to access to healthcare and to build commitment. A lot has been achieved, but there
Background image of page 3

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 4
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 10/24/2011 for the course MGMT 600 taught by Professor Dr.pal during the Spring '11 term at St. Johns Duplicate.

Page1 / 12

facing_the_challenge_one_year_on - FACING THE CHALLENGE ONE...

This preview shows document pages 1 - 4. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online